Mumbai, 26 May 2026:  Fermenta Biotech Limited, India’s leading manufacturer of premium-grade APIs, intermediates, and mixes of vitamins and minerals for the global markets, today announced that its consolidated revenue (other than from real estate) for the year ended 31 March 2026 was INR 538.4 crore, up 26% from the same year-ago period; EBITDA (other than from real estate) for the year ended 31 March 2026 was INR 120 crore, up 44% from the same year-ago period on the back of strong growth in Vitamin D3 - Human Nutrition. 

On the consolidated basis FY26 revenue (including real estate) was INR 547.8 crore (up 14% YoY), EBITDA INR 122.2 crore (up 0.5% YoY) and Profit after Tax INR 70.3 crore (down 8% YoY); the YoY decline in PAT reflects the high FY25 base created by one-time, near-pass-through real-estate value-unlocking inflows of INR 44.6 crore which was INR 1.6 crore in FY26.

Key financials (consolidated) without real estate

Key financials (consolidated) with real estate 

Revenue mix (consolidated)

Geographical Revenue Mix (consolidated) excluding real estate value unlocking

Performance highlights 

• Human nutrition segment volumes grew 21% over FY25.
• Animal nutrition segment volumes grew 49% over FY25 and average realization down by 16% over FY25.
• Green chemistry sales in FY26 more than doubled over FY25 on the back of new customer acquisitions. 
• Other Income grew 89% YoY to INR 22.4 crore, supported by a non-recurring insurance claim of INR 2.7 crore recognised in Q1FY26 and by higher foreign exchange gains on the back of a weaker rupee. Other Income sits above EBITDA and is therefore already reflected in the EBITDA growth reported above.
• Our German toll manufacturing subsidiary's FY26 revenue was INR 76.6 crore, up 101% YoY from a year ago, with EBITDA at INR 11.3 crore, down 18% YoY. Our US trading business subsidiary's FY26 revenue was INR 45.2 crore, down 10% from a year ago, with EBITDA at INR 1.9 crore loss against INR 0.5 crore loss in the same period a year ago.
• Continued utilisation of slow moving semi-finished inventory used in animal feed production resulted in further reversal of INR 3.1 crore in the current quarter.
• On 21 November 2025, the Government of India notified four new Labour Codes, which have been implemented in full and have resulted in a one-time, exceptional employee-benefit charge of INR 2.19 crore in FY26. 
• In the earlier years, the Company had recognised provision against investment, recoverable of expenses and trade receivable. In the current year out of such balances provided, company has recovered amount of INR 9.07 crore and accordingly provision has been reversed and recorded as an exceptional item.
• Reported PAT for FY26 is INR 70.3 crore, 8% lower than FY25. The headline decline reflects a high base: FY25 included INR 44.6 crore of real estate value-unlocking income, which was largely a one-off pass-through. Adjusting both years for this item, underlying PAT in FY26 is materially higher than in FY25 — in line with the 44% YoY growth in EBITDA. Two exceptional items, also affect the year-end numbers: a positive INR 9 crore write-back of doubtful-debt provisions made earlier; and a one-time INR 2.19 crore employee-benefit charge on adoption of the new Labour Codes. Stripped of one-offs, FY26 PAT is significantly stronger than FY25, consistent with the sharp rise in EBITDA.
• The board of directors have recommended dividend of Rs 3.75 per share.

Commenting on the results, Prashant Nagre, Managing Director, said:

“The turnaround of FY25 was further confirmed in FY26. While growth of revenue, excluding that from real estate unlocking, was 57% in FY25 over FY24, in FY26 revenue growth was 26% over FY25. On the underlying operating business, as explained above, with that one-time inflow stripped from both periods, PAT quality has in fact strengthened over the year. 

Our FY26 EBITDA (excluding real estate) demonstrates robust operational leverage— as it surpassed our FY25 EBITDA by 44%.

Our sustained efforts over the years in expanding the enzymes portfolio and their application & customer base have started yielding initial results. We are confident of continuing to expand & grow this portfolio.

While human nutrition volumes grew by 43% in FY25 over FY24, we have further seen the volumes grow by 21% in FY26 over FY25.

Our sustained volume momentum, combined with improving margins, positions Fermenta well for continued value creation.

We remain focused on scaling our core human nutrition business while exploring strategic opportunities. FY26 delivered the foundational layer for our two flagship product introductions — the granted Indian process patent for plant-based Vitamin D3 secured in September 2025, the EDQM Certificate of Suitability for the Vitamin D3 100 SD premix, and the Letter of Approval from the Global Alliance for Improved Nutrition. Commercial launches of VITADEE Green and Vitamin D3 100 SD are now sequenced for FY27, in line with the patent-certification-capacity-launch sequence appropriate to pharmaceutical-grade chemistry. Our ongoing capex at Dahej will establish commercial-scale production of plant-based Vitamin D3  (for which we hold Indian patent protection) alongside new Vitamin D3 derivatives. This strengthens our position as one of the world's leading fully integrated Vitamin D3 manufacturers.